Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

2017-09-01
Price :
Published : Sep-2017
No. of Pages : 77

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in July 2017. The industry reported 314 deals worth USD29.5 billion in July 2017, compared to 392 deals worth USD31.5 billion in June 2017. The oncology therapeutics market remained at the top in deal activity in July 2017 with 104 deals. In second place, infectious disease therapeutics market reported 60 deals. Licensing agreements in pharmaceutical and healthcare industry registered an increase in upfront payments. The segment reported USD203.7m as upfront payments in July 2017, compared to USD130m in June 2017. The number of deals in North America decreased to 203 in July 2017 from 254 in June 2017.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the six months.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Telehealth Market by Component Software & Services (RPM, RTM), Application (Teleradiology, telestroke, teleICU), Hardware (Glucose Meters), End-User (Provider, Payer, Patient), Delivery Mode (On-Premise, Cloud) Trends & Global Forecast to 2025

“The telehealth market is projected to grow at a CAGR of 16.9% during the forecast period (2020–2025).” The global telehealth market is projected to reach USD 55.6 billion by 2025 from USD 25.5 billion in 2020, at a CAGR of 16.9 % during the forecast period. The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, and government support and raising awareness. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. “The software & services segment will grow at the highest rate during the forecast period.” Base......
$4950

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

“The global biosimilars  market size is projected to register a CAGR of 24.7% during the forecast period.” The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market. “The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.” The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept......
$5650

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H1, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Post Operative Nausea And Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Post Operative Nausea And Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020" provides an overview of Seasonal Allergic Rhinitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Seasonal Allergic Rhinitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Cirrhosis Global Clinical Trials Review, H1, 2020

Cirrhosis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H1, 2020" provides an overview of Cirrhosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy